Peter Roselt

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu et al. · The Lancet Oncology · 2023 · 199 citations

Medicine, Oncology, Pharmacology +16

⁶⁴Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy

Rodney J. Hicks, Price Jackson, Grace Kong et al. · Journal of Nuclear Medicine · 2018 · 147 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA--first small animal PET results.

Gerald Reischl, Donna S. Dorow, Carleen Cullinane et al. · PubMed · 2007 · 112 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

A desferrioxamine B squaramide ester for the incorporation of zirconium-89 into antibodies

Stacey E. Rudd, Peter Roselt, Carleen Cullinane et al. · Chemical Communications · 2016 · 110 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17

PET imaging of tumours with a⁶⁴Cu labeled macrobicyclic cage amine ligand tethered to Tyr³-octreotate

Brett M. Paterson, Peter Roselt, Delphine Denoyer et al. · Dalton Transactions · 2013 · 101 citations

Medicine, Nuclear Medicine, Oncology +17